Key facts
- This page summarizes Sean Salmon's Form 4 filing for Medtronic plc (MDT).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 31 Jul 2024, 20:03.
Sean Salmon - 29 Jul 2024 Form 4 Insider Report for Medtronic plc (MDT)
- Reporting relationship
- EVP & President Cardiovascular
- Issuer ticker
- MDT
- Reported as of
- 29 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Jul 2024, 20:03:56 UTC
- Prior SEC filing
- 23 Feb 2024
- Next SEC filing
- 06 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas L. Osteraas, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sean Salmon filed Form 4 for Medtronic plc (MDT) on 31 Jul 2024.
Change
- Previous filing in this sequence was filed on 23 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MDT
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +14,375
- Change %
- +30%
- Price
- $0.000000
- Shares after
- 63,084
- Date
- 29 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MDT
transaction
Derivative
Performance Share Unit
Award
- Transaction value
- $0
- Shares
- +35,938
- Change %
- Price
- $0.000000
- Shares after
- 35,938
- Date
- 29 Jul 2024
- Ownership
- Direct
- Underlying class
- Performance Share Units
- Underlying amount
- 35,938
- Exercise price
- Footnotes
- F3, F4, F5
MDT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +106,260
- Change %
- Price
- $0.000000
- Shares after
- 106,260
- Date
- 29 Jul 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 106,260
- Exercise price
- $80.00
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The restrictions on the award shall lapse 100% on the third anniversary of the Grant Date.
Footnote F2
Includes 420 shares acquired through dividend reinvestment since the last report filed by the reporting person.
Footnote F3
Each performance share unit represents a contingent right to receive one share of Medtronic common stock.
Footnote F4
Vests on July 29, 2027.
Footnote F5
The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 35,938 shares will be issued. If maximum performance metrics are achieved, 71,876 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares.
Footnote F6
These options became exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant.